Erschienen in:
01.03.2015 | Review
Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer
verfasst von:
Ke-jun Liu, Ling-yu Ding, Hai-ying Wu
Erschienen in:
Tumor Biology
|
Ausgabe 3/2015
Einloggen, um Zugang zu erhalten
Abstract
Non-small cell lung cancer (NSCLC) accounts for about 85 % of all lung cancer cases. Patients with NSCLC often have an advanced disease at the time of diagnosis, with a 1-year survival rate about 10–15 % under the best support treatment. As therapeutic methods for lung cancer developed rapidly in recent years, the prognosis of stage IIIB or IV NSCLC also improve to a large extend. Bevacizumab is a monoclonal antibody against VEGFR which inhibits abnormal vascular growth in malignant tumors. In October 2006, bevacizumab was approved by the U.S. Food and Drug Administration (FDA) for first-line use in advanced NSCLC. For patients with advanced NSCLC who failed in previously platinum-based chemotherapy, bevacizumab also showed enhancing efficacy to antitumor drugs recommended by the latest NCCN guideline. This review intends to present the recent progress and prospects of bevacizumab in second- or third-line treatment for patients with refractory NSCLC.